Phs Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 4.00 M
as on 05-11-2024
- Paid Up Capital ₹ 4.00 M
as on 05-11-2024
- Company Age 4 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 6.11 Cr
as on 05-11-2024
- Revenue 82.11%
(FY 2023)
- Profit 57.70%
(FY 2023)
- Ebitda 131.07%
(FY 2023)
- Net Worth 130.82%
(FY 2023)
- Total Assets 86.30%
(FY 2023)
About Phs Life Sciences
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 4.00 M and a paid-up capital of Rs 4.00 M.
The company currently has active open charges totaling ₹6.11 Cr.
Vikrant Suryavanshi, Rucha Suryavanshi, Pravin Nalawade, and One other member serve as directors at the Company.
- CIN/LLPIN
U24121MH2020PTC336426
- Company No.
336426
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
22 Jan 2020
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Nashik, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Phs Life Sciences?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vikrant Suryavanshi  | Director | 22-Jan-2020 | Current |
| Pravin Nalawade | Director | 09-Nov-2021 | Current |
| Rucha Suryavanshi | Director | 16-Sep-2020 | Current |
| Hemant Pagar | Director | 10-Nov-2022 | Current |
Financial Performance of Phs Life Sciences.
Phs Life Sciences Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 82.11% increase. The company also saw a substantial improvement in profitability, with a 57.7% increase in profit. The company's net worth Soared by an impressive increase of 130.82%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Phs Life Sciences?
Unlock access to Phs Life Sciences's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Idbi Bank Limited Creation Date: 22 Nov 2023 | ₹2.40 Cr | Open |
Idbi Bank Limited Creation Date: 03 Jan 2023 | ₹7.10 M | Open |
Idbi Bank Limited Creation Date: 25 Mar 2022 | ₹3.00 Cr | Open |
How Many Employees Work at Phs Life Sciences?
Phs Life Sciences has a workforce of 0 employees as of May 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Phs Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Phs Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
